Wendy L. Devine

I'll research this attorney before drafting the summary.

Let me verify the Guardant/Tempus matter and her bar/education details.

Let me confirm a couple of outcomes and the Federal Circuit appeal details.

Wendy L. Devine — Patent Litigation Practice Summary

Specialty / focus. Devine is a San Francisco-based litigation partner at Wilson Sonsini Goodrich & Rosati, where she leads (described in firm materials as co-chair of) the firm's patent litigation practice group. Her practice centers on life sciences patent disputes: Hatch-Waxman/ANDA and biosimilar litigation, pharmaceutical method-of-treatment and formulation patents, biotechnology, medical devices, and diagnostics. Her firm bio also lists food science/food technology, trademarks, and trade secrets, and notes a scientific background in genetics and animal science that she draws on in life-science matters. The tracked docket fits that profile — Hatch-Waxman/pharma (Azurity v. Helsinn) and molecular diagnostics/cancer screening (Guardant v. Tempus) — while reported matters extend into plant-based food (Impossible Foods) and spinal implants (NuVasive v. Alphatec). She does not appear to be a Wi-Fi/standards-essential or consumer-software litigator.

Side preference. All three tracked appearances are plaintiff-side, and reported work is predominantly for patent owners and branded/generic pharmaceutical clients asserting or defending patents. That said, her practice is not one-directional: she has represented generic challengers (Mylan/Viatris) invalidating brand patents in IPR, and Wilson Sonsini describes her as having "extensive" experience "for prominent companies on both sides" of pharmaceutical patent litigation, with Patexia recognizing her for representing both plaintiffs and defendants in ANDA matters. The all-plaintiff tracked count therefore reflects a limited sample, not a claimant-only practice.

Firm context. Devine has been at Wilson Sonsini her entire tracked career, joining the firm in 2006 and becoming a partner in the 2018 partner class. No prior firm history surfaced in available sources; she has no in-house role.

Notable matters and outcomes.

• Bayer Pharma AG v. Mylan Pharmaceuticals Inc., No. 23-2434 (Fed. Cir. Sept. 23, 2025) — she argued for all appellees and led the Wilson Sonsini team that persuaded the Federal Circuit to affirm the PTAB's holding that claims 1–4 of U.S. Patent 10,828,310 (Xarelto/rivaroxaban) were unpatentable; the court vacated the holding as to claims 5–8 on a claim-construction issue and remanded. The firm's own release framed this as an affirmance of "key patent claims"; the decision was in fact affirmed-in-part and vacated-in-part.
• Impossible Foods Inc. v. Motif Foodworks, Inc. (D. Del.) — lead counsel for Impossible Foods in the first patent suit in the plant-based food industry; the team defended six IPRs and defeated motions to dismiss and to stay before the case settled shortly before trial.
• Guardant Health, Inc. v. Tempus AI, Inc. (D. Del. 24-cv-687, consolidated with 25-cv-1013) — her tracked lead-counsel matter; Guardant asserts cancer-diagnostic patents against Tempus. Tempus has petitioned for IPR on several asserted patents; the consolidated case is scheduled for a Markman hearing in October 2026 and jury trial in October 2028, so no substantive outcome is yet reported.
• Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. — the two tracked back-up counsel entries correspond to Azurity's IPR challenges (IPR2025-00945 through -00949) to Helsinn patents on antiemetic/chemotherapy-induced nausea and vomiting methods and compositions; the PTAB instituted review on all five petitions in late 2025. She is also reported as defending Azurity's patents in related Hatch-Waxman suits, including Azurity v. Amneal (Katerzia), which settled shortly before trial.

PTAB / IPR experience. Yes — she appears regularly in PTAB proceedings. Her tracked Azurity matters are IPRs, she was back-up counsel in the Xarelto IPRs (IPR2022-00517 and related), and she argued the resulting Federal Circuit appeal. Her PTAB role tends to be as part of a team that pairs a Washington/Seattle-based lead (e.g., Richard Torczon) with her San Francisco-based litigation counsel.

Bar / education. Admitted to the State Bar of California and registered to practice before the U.S. Patent and Trademark Office (Reg. No. 61,309); J.D., University of San Diego School of Law; M.S. and B.S. in Animal Science (genetics emphasis), University of California, Davis.

Note on sourcing: the practice description and matter results above are drawn from Wilson Sonsini firm materials and court/PTAB filings; the Guardant v. Tempus litigation remains pending, and the exact disposition of the two tracked Azurity v. Helsinn entries (and whether they are duplicative docket entries for the same or related IPRs) cannot be fully confirmed from public filings.